Takeda snags rights to lupus drugs from Seattle upstart in $255M deal
by Chris Burton
New therapies have been slow to reach the market, leaving patients with limited options to combat the chronic inflammation and tissue damage from the disease. Resolve’s lead compound, the key asset in its Takeda deal, could advance treatment of lupus with its novel mechanism that attacks triggers of the disease called immune complexes.
Read more: Takeda snags rights to lupus drugs from Seattle upstart in $255M deal – FierceBiotech http://www.fiercebiotech.com/story/takeda-snags-rights-lupus-drugs-seattle-upstart-255m-deal/2013-02-27#ixzz2MXaBxdWF